ArticleInternational journal of hematology2025
Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients.
Kazuhito Suzuki et al.PubMed ↗Publisher ↗
No numbers read from the abstract.